ABCL Stock Cash Flow Statements

AbCellera Biologics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

AbCellera Biologics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities:
net income	-34,727,000	-45,621,000		-51,107,000	-36,930,000	-40,610,000						26,624,000	-6,785,000	168,573,000		-21,382,000	-2,323,000	117,221,000
depreciation of property and equipment	4,542,000	4,409,000	2,100,000	3,834,000	3,448,000	3,155,000	3,884,000	3,064,000	2,952,000	2,858,000	2,741,000	2,531,000	2,290,000	1,391,000	1,343,000	1,163,000	1,057,000	840,000
amortization and impairment of intangible assets			10,464,000	33,085,000
amortization of operating lease right-of-use assets	1,589,000	1,274,000	1,336,000	1,376,000	1,515,000	1,922,000	1,573,000	1,674,000	1,646,000	1,606,000	1,573,000	1,566,000	1,144,000	976,000	890,000
stock-based compensation	14,207,000	14,786,000	15,226,000	17,164,000	17,782,000	17,409,000	16,448,000	15,862,000	16,399,000	15,474,000	13,323,000	11,754,000	12,113,000	12,291,000	9,038,000	7,708,000	8,473,000	5,427,000
fair value gain on contingent consideration
other					-9,900,000	1,707,000	6,631,000	-1,925,000	-795,000	-3,634,000	5,243,000	3,602,000	294,000	-592,000	2,682,000	1,307,000	-228,000	-191,000
changes in operating assets and liabilities:
research fees and grants receivable	-11,391,000	-1,133,000		-19,824,000	-15,858,000	-18,576,000
income taxes receivable
accounts payable and accrued liabilities	-3,947,000	-3,409,000	6,617,000	4,148,000	4,748,000	-4,878,000		975,000	2,951,000	-5,778,000	2,217,000	731,000	-2,633,000	751,000	1,713,000	3,327,000	1,554,000	-5,194,000
deferred revenue	-3,952,000	13,313,000	5,543,000	-692,000	-4,765,000	-8,017,000	-6,738,000	-2,368,000	-965,000	-3,905,000	10,277,000	-1,115,000	-3,920,000	941,000	-427,000	4,203,000	-1,238,000	6,086,000
deferred grant income	-461,000	-1,220,000	3,296,000	10,914,000	8,479,000	11,278,000	9,144,000	4,811,000								4,975,000
other assets	6,130,000	7,320,000	4,946,000	2,481,000	2,132,000	-3,605,000	4,661,000	9,152,000	1,230,000	-6,063,000		2,913,000	3,418,000	-7,557,000		299,000
net cash from operating activities	-32,404,000	-11,554,000	-8,000,000	-28,882,000	-29,966,000	-41,708,000	-19,611,000	-106,000	19,903,000	-44,063,000	30,912,000	-126,786,000	273,015,000	100,219,000	-16,712,000	-5,932,000	157,683,000	109,545,000
capex	-13,365,000	-10,636,000	-15,630,000	-18,516,000	-20,110,000	-24,140,000	-14,431,000	-20,331,000	-27,201,000	-14,984,000	-12,330,000	-12,513,000	-31,322,000	-14,495,000	-9,430,000	-8,574,000	-36,804,000	-3,644,000
free cash flows	-45,769,000	-22,190,000	-23,630,000	-47,398,000	-50,076,000	-65,848,000	-34,042,000	-20,437,000	-7,298,000	-59,047,000	18,582,000	-139,299,000	241,693,000	85,724,000	-26,142,000	-14,506,000	120,879,000	105,901,000
cash flows from investing activities:
purchases of property and equipment	-13,365,000	-10,636,000	-15,630,000	-18,516,000	-20,110,000	-24,140,000	-14,431,000	-20,331,000	-27,201,000	-14,984,000	-12,330,000	-12,513,000	-31,322,000	-14,495,000	-9,430,000	-8,574,000	-36,804,000	-3,644,000
purchase of marketable securities	-126,552,000	-164,990,000	-152,837,000	-186,242,000	-176,636,000	-249,371,000	-276,836,000	-215,783,000	-168,139,000	-360,752,000		-536,124,000	-82,532,000	-51,774,000	-29,396,000
proceeds from marketable securities	113,410,000	190,027,000	201,893,000	196,604,000	232,840,000	306,545,000	268,024,000	220,099,000	160,176,000	262,638,000	92,393,000	272,430,000	88,514,000	57,294,000	18,081,000
receipt of grant funding	5,430,000	1,018,000	6,558,000	9,400,000	12,582,000	7,168,000	10,288,000	7,330,000	5,000,000	2,693,000	2,334,000	6,002,000	5,502,000	2,596,000	22,814,000	5,287,000
long-term investments and other assets	-8,182,000	-5,601,000	-2,611,000	9,588,000	8,335,000	-4,385,000	-7,892,000	0	-2,022,000	-34,735,000		-5,713,000	0	-11,657,000
investment in equity accounted investees	-2,552,000	-1,883,000		-7,136,000	-4,913,000	-5,907,000
net cash from investing activities	-31,811,000	7,935,000	35,703,000	3,698,000	52,098,000	29,910,000	-24,323,000	-12,786,000	-34,390,000	-149,609,000	-17,063,000	-281,994,000	-27,197,000	-26,371,000	-1,149,000	-269,626,000	-45,633,000	-15,839,000
cash flows from financing activities:
payment of contingent consideration and other
proceeds from long-term liabilities and exercise of stock options	5,505,000	6,148,000
net cash from financing activities	-3,375,000	5,970,000	4,142,000	3,145,000	2,651,000	2,831,000	3,765,000	6,630,000	419,000	-458,000	349,000	-19,000	1,173,000	-3,131,000	1,834,000	898,000	-5,075,000	-1,543,000
effect of exchange rate changes on cash and cash equivalents	761,000	590,000	-2,160,000	367,000	-43,000	-781,000	1,068,000	-1,063,000	797,000	-213,000	364,000	-8,552,000	-1,207,000	-204,000	-525,000	-217,000	-199,000	-484,000
increase in cash and cash equivalents	-66,829,000	2,941,000							-13,271,000	-194,343,000			245,784,000	70,513,000	-16,552,000	-274,877,000	106,776,000	91,679,000
cash and cash equivalents and restricted cash, beginning of period	0	183,615,000	0	0	0	160,610,000	-1,000	0	1,000	414,650,000		0	0	501,142,000
cash and cash equivalents and restricted cash, end of period	-66,829,000	186,556,000	29,685,000	-21,672,000	24,740,000	150,862,000	-39,102,000	-7,325,000	-13,270,000	220,307,000		-417,351,000	245,784,000	571,655,000
restricted cash included in other assets	0	2,290,000	0	0	0	2,290,000	0	0	0	2,290,000		4,939,000
total cash, cash equivalents, and restricted cash shown on the balance sheet	-66,829,000	184,266,000	29,685,000	-21,672,000	24,740,000	148,572,000	-39,102,000	-7,325,000
supplemental disclosure of non-cash investing and financing activities
property and equipment in accounts payable	1,773,000	10,960,000	-3,222,000	45,000	-2,710,000	18,654,000	677,000	1,230,000	2,800,000	8,918,000
right-of-use assets obtained in exchange for operating lease obligation	66,426,000	3,361,000	-334,000	1,780,000	345,000	107,000	-2,387,000	641,000	821,000	2,124,000	4,455,000	47,035,000	-1,454,000	658,000	9,662,000	-2,597,000	15,385,000	14,188,000
amortization of intangible assets		922,000				1,689,000		2,671,000	2,658,000	2,656,000		2,631,000	2,607,000	2,606,000	2,630,000	2,502,000	2,465,000	2,465,000
fair value gain on contingent consideration and other		2,213,000
income taxes payable		-4,408,000		-2,756,000	-2,771,000	-3,182,000		5,801,000	35,498,000	-12,614,000	-53,675,000	-87,185,000	-17,714,000	69,965,000	16,033,000	767,000	-24,207,000	-6,123,000
payment of liability for in-licensing agreement and other		-178,000	-177,000	-184,000	-183,000	-185,000
net earnings							-47,150,000	-28,610,000	-30,528,000	-40,110,000
fair value (gain) loss on contingent consideration and investments
research fee and grant receivable							-10,438,000
accrued royalties receivable							0	13,000	0	9,260,000	85,205,000	-62,617,000	274,497,000	-167,914,000	-134,463,000	21,559,000	145,907,000	26,861,000
income taxes (payable) receivable
purchase of intangible assets							0				0
investment in and loans to equity accounted investees							-3,476,000	-3,541,000	-2,204,000	-4,469,000	-5,909,000	-4,076,000	-7,359,000	-8,335,000	-3,218,000	-6,595,000
fair value gain on contingent consideration and investments
deferred income tax and other
accrued royalties payable								0	0	-16,253,000	1,524,000	-32,733,000	5,192,000	22,857,000	21,911,000	-22,925,000	3,511,000	-7,134,000
proceeds from long-term liabilities				3,102,000	2,373,000	2,124,000
proceeds from exercise of stock options				227,000	461,000	892,000
decrease in cash and cash equivalents						-9,748,000	-39,101,000
deferred tax (expense) recovery
change in fair value of contingent consideration and investments
accounts payable and other liabilities
acquisitions
payment of liability for in-licensing agreement, contingent consideration, and other							-185,000
proceeds from long-term debt and exercise of stock options										490,000
accounts and accrued research fees receivable									-32,184,000	7,915,000	-19,040,000	3,288,000	1,788,000	-8,751,000	-3,057,000	-5,990,000	1,734,000	-30,073,000
payment of liability for in-licensing agreement and contingent consideration									271,000	-948,000
proceeds (repayment) from long-term debt and exercise of stock options
deferred grant revenue										4,525,000	2,634,000	1,224,000	724,000	4,682,000
total cash, cash equivalents and restricted cash shown on the balance sheet										218,017,000
deferred tax expense															1,249,000	-4,023,000	133,000	623,000
operating lease liabilities															-451,000	37,000
other operating assets and liabilities
purchases of marketable securities
acquisitions, net of cash acquired
long-term investments and other
repayment of long-term debt and contingent consideration											0	-250,000	-1,000	-72,000
proceeds from convertible debentures
net proceeds from issuance of common shares
proceeds from issuance of preferred shares - series a1 and a2 financing
cash and cash equivalents and restricted cash, beginning of year
cash and cash equivalents and restricted cash, end of year
restricted cash included within other current and other long-term assets
total cash, cash equivalents, and restricted cash shown on the balance sheets
supplemental disclosure of non-cash investing and financing activities:
property and equipment purchases in accounts payable
purchase of intangible assets in exchange for in-licensing agreement payable
proceeds from debt and exercise of stock options												231,000
payment of liability for in-licensing agreement												0	940,000	-5,000,000	0	0
total cash, cash equivalents and restricted cash shown in the statement of cash flows													244,897,000	570,718,000
property plant and equipment in accounts payable													-207,000	2,353,000				423,000
proceeds from long-term debt and issuance of common shares pursuant to exercise of stock options														1,941,000
restricted cash included in other long-term assets														-937,000
repayment (issuance) of related party loans
repayment of long-term debt															0	0	-107,000	-1,716,000
proceeds from long-term debt															0	0
payment of contingent consideration															0	0
short-term borrowings
issuance of common shares pursuant to exercise of stock options and other
repayment of loan to related parties
long-term investments and deposits
issuance of common shares pursuant to exercise of stock options																898,000	1,710,000	173,000
proceeds from issuance of preferred shares - series a2 financing
cash and cash equivalents, beginning of period																0	0	594,116,000
cash and cash equivalents, end of period																-274,877,000	106,776,000	685,795,000
amortization of operating lease right-of-use-assets																	693,000	661,000
long-term investments
other assets and liabilities																		-1,924,000
investment in equity investees																		-12,195,000
payment of deferred financing fees
extinguishment of long-term debt
accretion and other
unrealized foreign exchange gains and losses
investment tax credit receivable
acquisition of trianni
proceeds from issuance of preferred shares - series a1 financing
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year

We provide you with 20 years of cash flow statements for AbCellera Biologics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AbCellera Biologics stock. Explore the full financial landscape of AbCellera Biologics stock with our expertly curated income statements.

The information provided in this report about AbCellera Biologics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.